American Journal of Transplantation最新文献

{"title":"West Nile Virus and Other Nationally Notifiable Arboviral Diseases - United States, 2023.","authors":"Marcus Pereira","doi":"10.1016/j.ajt.2025.06.032","DOIUrl":"https://doi.org/10.1016/j.ajt.2025.06.032","url":null,"abstract":"","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":" ","pages":""},"PeriodicalIF":8.9,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144574555","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reply to Malik and Patel.","authors":"Matthew M Byrne, Koji Tomiyama, Roberto Hernandez-Alejandro","doi":"10.1016/j.ajt.2025.06.031","DOIUrl":"https://doi.org/10.1016/j.ajt.2025.06.031","url":null,"abstract":"","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":" ","pages":""},"PeriodicalIF":8.9,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144566856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Liver transplantation for hepatitis D virus/hepatitis B virus coinfection in Italy: An intention-to-treat analysis of long-term outcomes","authors":"Roberta Angelico ,&nbsp;Silvia Trapani ,&nbsp;Tommaso Maria Manzia ,&nbsp;Ilaria Lenci ,&nbsp;Paolo Grossi ,&nbsp;Andrea Ricci ,&nbsp;Patrizia Burra ,&nbsp;Enzo Andorno ,&nbsp;Salvatore Agnes ,&nbsp;Sherrie Bhoori ,&nbsp;Umberto Baccarani ,&nbsp;Luca S. Belli ,&nbsp;Paola Carrai ,&nbsp;Lucio Caccamo ,&nbsp;Amedeo Carraro ,&nbsp;Matteo Cescon ,&nbsp;Michele Colledan ,&nbsp;Umberto Cillo ,&nbsp;Luciano De Carlis ,&nbsp;Nicola De Maria ,&nbsp;Mario Angelico","doi":"10.1016/j.ajt.2025.03.003","DOIUrl":"10.1016/j.ajt.2025.03.003","url":null,"abstract":"<div><div>Patients with hepatitis D virus (HDV)/hepatitis B virus (HBV)-related end-stage liver disease candidates for liver transplantation (LT) have traditionally been regarded as a special population, although their outcomes are controversial. An intention-to-treat (ITT) analysis of long-term outcomes of HDV/HBV-coinfected patients waitlisted for LT in Italy, between 2011 and 2020, was performed and compared with HBV-monoinfected LT candidates. Of 1731 HBV-infected LT candidates, 1237 (71.5%) had HBV monoinfection and 494 (28.5%) HDV/HBV coinfection. At listing, HDV/HBV-coinfected patients were significantly younger, listed mainly for decompensated cirrhosis, and with fewer hepatocellular carcinoma (HCC) cases; (26% vs 65.8%; <em>P</em> &lt;.0001) compared with HBV-monoinfected patients. HDV/HBV-coinfected patients showed better 5-year ITT survival (83.2%; 95% CI: 79.4%-83.4%, vs 71.6%; 95% CI: 68.8%-74.2%; <em>P</em> &lt; .0001). ITT-multivariable analysis identified the presence of HCC, advanced recipient age, and high model for end-stage liver disease-Na scores as mortality risk factors. Five years after LT, 99.1% of HDV/HBV-coinfected patients received oral nucleos(t)ide analogs, with immunoglobulins against antigen of the hepatitis B virus in 91.8% of cases. HBV and HDV viral recurrences were 1.1% and 0.2%, respectively, whereas recurrent or de novo HCC were 8.9% and 0.3%, respectively. In Italy, HDV/HBV-coinfected patients waitlisted for LT showed more favorable outcomes compared with HBV-monoinfected patients, both before and after LT. These excellent results, from the largest cohort reported so far, suggest that HDV/HBV-coinfected LT recipients do not represent a risky population and may be considered for simpler long-term antiviral prophylactic strategies.</div></div>","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":"25 7","pages":"Pages 1502-1514"},"PeriodicalIF":8.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143583999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is operational tolerance induction finally safe and feasible for some kidney transplant recipients: A breakthrough to a new horizon?","authors":"Edward K. Geissler ,&nbsp;Birgit Sawitzki","doi":"10.1016/j.ajt.2025.02.013","DOIUrl":"10.1016/j.ajt.2025.02.013","url":null,"abstract":"","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":"25 7","pages":"Pages 1386-1387"},"PeriodicalIF":8.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143490113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Can mouse kidney transplant models inform mechanisms of injury and acceptance in clinical kidney transplantation?","authors":"Zheng Jenny Zhang ,&nbsp;Federica Casiraghi ,&nbsp;Griffith Boord Perkins ,&nbsp;William M. Baldwin 3rd ,&nbsp;Robert L. Fairchild","doi":"10.1016/j.ajt.2025.04.001","DOIUrl":"10.1016/j.ajt.2025.04.001","url":null,"abstract":"<div><div>Despite standard-of-care immunosuppression, acute rejection remains commonly observed in kidney transplants and leads to chronic graft injury and failure in many transplanted patients. Mechanisms underlying acute and chronic kidney graft injury are incompletely understood, undermining the development and implementation of therapeutic strategies to improve outcomes. This compels the use of preclinical kidney transplant models to identify components and mechanisms mediating acute and chronic graft injury. Mouse models have been instrumental in establishing basic principles of alloimmune responses and the rejection of heart allografts. There is increasing use of mouse models to extend these studies to kidney transplantation, but the relevance of the findings to clinical kidney transplants remains under scrutiny. Here, we discuss the strengths and weaknesses of mouse models of kidney allograft responses and injury. Although obvious weaknesses arise when considering the relevance to clinical kidney transplants, there are new models that recapitulate many features of kidney graft injury in the clinical scenario and have much to contribute to understanding innate and donor alloantigen-specific mechanisms underlying kidney allograft injury. As in most preclinical studies, the pertinent use of kidney allogeneic transplants in mice comes down to the judicious choice of test questions and the choice of appropriate donors and recipients for the chosen model.</div></div>","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":"25 7","pages":"Pages 1391-1398"},"PeriodicalIF":8.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143822623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute retroperitoneal bleeding 1 month after kidney transplantation","authors":"Mahnoor Zia ,&nbsp;Charudatta Bavare ,&nbsp;Luan Troung ,&nbsp;Mark J. Hobeika","doi":"10.1016/j.ajt.2025.02.008","DOIUrl":"10.1016/j.ajt.2025.02.008","url":null,"abstract":"","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":"25 7","pages":"Pages 1579-1581"},"PeriodicalIF":8.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144517197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of repeat human leukocyte antigen mismatches on kidney graft survival: A contemporary Collaborative Transplant Study analysis","authors":"Lissa Pipeleers ,&nbsp;Christian Unterrainer ,&nbsp;Marie-Paule Emonds ,&nbsp;Karl Martin Wissing ,&nbsp;Thuong Hien Tran","doi":"10.1016/j.ajt.2024.12.014","DOIUrl":"10.1016/j.ajt.2024.12.014","url":null,"abstract":"<div><div>Repeat human leukocyte antigen (HLA) mismatches (RMM) have been historically associated with an increased risk of graft loss after repeat kidney transplantation, in particular HLA-DR RMM in sensitized recipients. As routine use of sensitive assays can at present prevent the transplantation of RMM in hosts with donor-specific antibodies, we hypothesized that RMM would no longer be associated with graft loss. We performed a registry analysis of the Collaborative Transplant Study database including 6711 patients who received a second kidney transplant (KT) between 2010 and 2021, with at least 1 HLA-A, HLA-B, or HLA-DR mismatch. No increased risk for graft loss was observed for the second KT with a class I RMM, regardless of sensitization status. For the second KT with a HLA-DR RMM, the hazard ratio for graft loss in the first year after transplantation was 1.61 (95% CI 1.16-2.23; <em>P</em> = .004) compared to recipients without an RMM and increased to 2.21 (95% CI 1.24-3.63: <em>P</em> = .002) in sensitized recipients (latest complement-dependent cytotoxicity panel reactive antibodies &gt;0%). Our observations suggest that class I RMM do not need to be systematically avoided. In contrast, HLA-DR RMM still had a negative impact on graft survival in this contemporary cohort, despite the widespread availability of Luminex.</div></div>","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":"25 7","pages":"Pages 1481-1490"},"PeriodicalIF":8.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142880827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Predicting the success of antibody removal with therapeutic plasma exchange: The role of serum dilutions","authors":"Nidhi Vantair ,&nbsp;Maria Leising ,&nbsp;Matthew Najor ,&nbsp;Yazan Juma ,&nbsp;Dong Hyang Kwon ,&nbsp;Bhaskar Kallakury ,&nbsp;Alexander Gilbert ,&nbsp;Jennifer E. Verbesey ,&nbsp;Maria E. Rodrigo ,&nbsp;Farooq H. Sheikh ,&nbsp;Alaa Ali ,&nbsp;Anne Renteria ,&nbsp;Matthew Cooper ,&nbsp;Sandra Rosen-Bronson ,&nbsp;Olga A. Timofeeva","doi":"10.1016/j.ajt.2025.03.022","DOIUrl":"10.1016/j.ajt.2025.03.022","url":null,"abstract":"<div><div>Therapeutic plasma exchange (TPE) remains a primary therapy for addressing circulating donor-specific antibodies against mismatched human leukocyte antigens, which pose a significant challenge to successful transplantation of solid organs and hematopoietic cells. In this study, we aimed to evaluate the response to 5 TPE sessions in patients undergoing desensitization, as well as in patients who developed antibody-mediated rejection posttransplant. Sera collected before and after each TPE session was treated with EDTA and tested using the single-antigen bead assay as undiluted or 1:4, 1:16, 1:64, and 1:256 diluted. The reduction in human leukocyte antigen antibodies correlated with previously established total immunoglobulin G reduction levels. However, we observed that class I antibody levels were reduced by 85% to 90% while class II antibodies were reduced by only 75% to 80% after 5 TPE sessions. We also found that dilutions performed on pretreatment serum were predictive of the response to TPE. This approach was used to design TPE-based desensitization protocols for highly sensitized patients across various organ and tissue types, as well as for treating patients with antibody-mediated rejection. Our data suggest that serum dilution may be an effective method for assessing the likelihood of response to TPE, thereby aiding in the guidance of treatment strategies.</div></div>","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":"25 7","pages":"Pages 1491-1501"},"PeriodicalIF":8.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143750383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter in reference to “Immunomodulation of T cell-mediated alloimmunity by proximity to endothelial cells under mTOR blockade”","authors":"Shuang Li ,&nbsp;Dawei Zou","doi":"10.1016/j.ajt.2025.03.023","DOIUrl":"10.1016/j.ajt.2025.03.023","url":null,"abstract":"","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":"25 7","pages":"Pages 1582-1583"},"PeriodicalIF":8.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143741760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Microvascular inflammation in kidney allografts: New directions for patient management","authors":"Georg A. Böhmig ,&nbsp;Alexandre Loupy ,&nbsp;Marta Sablik ,&nbsp;Maarten Naesens","doi":"10.1016/j.ajt.2025.03.031","DOIUrl":"10.1016/j.ajt.2025.03.031","url":null,"abstract":"<div><div>Microvascular inflammation (MVI) is a key histological feature of immune-mediated injury at the capillary interface of renal allografts, characterized by immune cell infiltration into glomerular and peritubular capillaries. Although traditionally associated with antibody-mediated rejection (AMR), many MVI cases lack detectable donor-specific antibodies (DSA), suggesting the involvement of antibody-independent immune mechanisms or alternative triggers, such as viral infections or ischemia-reperfusion injury. The Banff 2022 scheme introduced a subcategory, “MVI, DSA-negative, C4d-negative,” within an overarching AMR or MVI category. This subcategory—similar to AMR—was shown to carry a significant risk of graft failure. Its recognition marks a major advancement, offering a robust framework for investigating the pathophysiology of MVI, which may involve a wide array of overlapping triggers. Emerging evidence from transcriptome analyses highlights natural killer cells as possible effectors, regardless of DSA status. Therapies targeting natural killer cells, particularly the anti-CD38 antibody felzartamab, have shown promising reductions in MVI and molecular injury. Notably, the US Food and Drug Administration has approved an MVI-based primary endpoint for a phase 3 trial evaluating this approach, representing a critical step toward the development of new therapeutics. Recognizing MVI as a multifaceted histological phenotype—driven by diverse triggers—may signal a paradigm shift in transplant medicine.</div></div>","PeriodicalId":123,"journal":{"name":"American Journal of Transplantation","volume":"25 7","pages":"Pages 1410-1416"},"PeriodicalIF":8.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}